Related Experiment Videos
Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3
Min Xie1, Ming Sun1, Ya-nan Zhu1
1Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
Abstract:
Current evidence suggests that long noncoding RNAs (lncRNAs) may be an important class of functional regulators involved in human cancers development, including gastric cancer (GC). Here, we reported that HOXA cluster antisense RNA2 (HOXA-AS2), a 1048bp RNA, was upregulated in GC. Increased HOXA-AS2 expression in GC was associated with larger tumor size and higher clinical stage; patients with higher levels of HOXA-AS2 expression had a relatively poor prognosis. Further experiments revealed that HOXA-AS2 knockdown significantly inhibited GC cells proliferation by causing G1 arrest and promoting apoptosis, whereas HOXA-AS2 overexpression promoted cell growth. Furthermore, HOXA-AS2 could epigenetically repress the expression of P21, PLK3, and DDIT3 via binding with EZH2 (enhaner of zeste homolog 2), a key component of PRC2; ChIP assays demonstrated that EZH2 could directly bind to the promoter of P21, PLK3 and DDIT3, inducing H3K27 trimethylated. In conclusion, these data suggest that HOXA-AS2 could be an oncogene for GC partly through suppressing P21, PLK3, and DDIT3 expression; HOXA-AS2 may be served as a candidate prognostic biomarker and target for new therapies in human GC.
Insights
HOXA-AS2, a long noncoding RNA (lncRNA), is upregulated in gastric cancer (GC) and promotes tumor growth. It acts as an oncogene by epigenetically silencing tumor suppressor genes, suggesting its potential as a GC biomarker and therapeutic target.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized as critical regulators in human cancer development.
- Gastric cancer (GC) pathogenesis involves complex molecular alterations, including the dysregulation of lncRNAs.
Purpose of the Study:
- To investigate the role of HOXA cluster antisense RNA2 (HOXA-AS2) in gastric cancer.
- To elucidate the molecular mechanisms underlying HOXA-AS2's function in GC progression.
Main Methods:
- Quantitative real-time PCR to assess HOXA-AS2 expression levels in GC tissues and cell lines.
- Cell proliferation assays, cell cycle analysis, and apoptosis assays to evaluate the functional impact of HOXA-AS2.
- Chromatin immunoprecipitation (ChIP) assays and Western blotting to investigate the interaction between HOXA-AS2, EZH2, and target gene promoters.
Main Results:
- HOXA-AS2 expression was significantly upregulated in GC tissues and correlated with advanced tumor size, higher clinical stage, and poorer patient prognosis.
- HOXA-AS2 knockdown inhibited GC cell proliferation by inducing G1 arrest and apoptosis, while its overexpression promoted cell growth.
- HOXA-AS2 epigenetically repressed the expression of P21, PLK3, and DDIT3 by recruiting EZH2 to their promoter regions, leading to H3K27 trimethylation.
Conclusions:
- HOXA-AS2 functions as an oncogene in gastric cancer, partly by suppressing the expression of P21, PLK3, and DDIT3.
- HOXA-AS2 represents a potential prognostic biomarker and a promising therapeutic target for gastric cancer.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Inheritance of Chromatin Structures
Abnormal Proliferation